Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
SRNE Shariah Compliance
Screening Methodology: AAOIFI
HALAL
Last Updated: August 21, 2023
Report Source: 2023 2nd Quarter Report
Sorrento Therapeutics Inc. Stock Analysis SRNE
United States Health Care Nano Cap Report: Sorrento Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. The company is headquartered in San Diego, California and currently employs 949 full-time employees. The company went IPO on 2007-01-19. The firm is engaged in developing a portfolio of next-generation treatments for cancer, infectious diseases and pain. The company is also developing Resiniferatoxin (RTX), a naturally occurring non-opioid ultra-potent transient receptor potential vanilloid-1 agonist. The Company’s proprietary fully human G-MAB antibody library and ACEA small molecule library are the pipeline of new solutions for cancer. Its diagnostics platforms include the COVIMARK lateral flow antigen test and the VIREX platform.
Read More Sorrento Therapeutics Inc (SRNE) Chart
Key Statistics of Sorrento Therapeutics Inc (SRNE)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.00Volume
110.26KP/E Ratio (TTM)
-52 Week Range
Market Cap
275.64KAvg. Volume
347.67KDividend Yield
-Financial Metrics & Statements of Sorrento Therapeutics Inc (SRNE)
FAQ's for Sorrento Therapeutics Inc (SRNE)
- According to Musaffa’s Shariah screening methodology, Sorrento Therapeutics Inc (SRNE) is currently classified as HALAL as of August 2023. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Sorrento Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Sorrento Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Sorrento Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Sorrento Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Sorrento Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.